Robert Charles Jahr - 21 Jul 2026 Form 4 Insider Report for Outlook Therapeutics, Inc. (OTLK)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: OTLK
Reported as of: 21 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jul 2026, 19:34:19 UTC
Prior SEC filing: 09 Jul 2025
Next SEC filing: 14 Aug 2026
Source filing: View source filing
Reporting owner signature: Lawrence Kenyon, Attorney-in-Fact

Key filing fact

Robert Charles Jahr filed Form 4 for Outlook Therapeutics, Inc. (OTLK) on 23 Jul 2026.

Key facts

This page summarizes Robert Charles Jahr's Form 4 filing for Outlook Therapeutics, Inc. (OTLK).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 23 Jul 2026, 19:34.

Change

Previous filing in this sequence was filed on 09 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002076177 Primary reporting owner

Jahr Robert Charles

Relationship: Chief Executive Officer, Director
Address: C/O OUTLOOK THERAPEUTICS, INC., 111 S. WOOD AVE, UNIT #100, ISELIN
Signature: Lawrence Kenyon, Attorney-in-Fact
Signature date: 23 Jul 2021

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OTLK transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +100,000
Change %
Price: $0.000000^*
Shares after: 100,000
Date: 21 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $1.43
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option was granted to Mr. Jahr on July 21, 2026, pursuant to the Issuer's 2024 Equity Incentive Plan and the Issuer's standard form of stock option agreement thereunder. The option vests and becomes exercisable in full on July 21, 2027, subject to Mr. Jahr's continuing service with the Issuer through such vesting date.